Jagsonpal to acquire 85% stake in Aequitas for ₹20.8 crore
Jagsonpal Pharmaceuticals has agreed to acquire an 85% stake in Aequitas Healthcare Private Limited for ₹20.8 crore to enter the hospital segment. The transaction, funded by internal accruals, is expected to close by July 15, 2026, and provides access to institutional networks.
*this image is generated using AI for illustrative purposes only.
Jagsonpal Pharmaceuticals has entered into a definitive agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited for a cash consideration of ₹20.8 crore. The transaction, announced on June 29, 2026, marks the company's strategic entry into the hospital segment and is aimed at gaining immediate access to institutional networks. The acquisition is expected to be completed by July 15, 2026, subject to the fulfilment of customary closing conditions.
Aequitas Healthcare, incorporated in 2017, is a Mumbai-based pharmaceutical entity engaged in the sale and distribution of products to hospitals. The target company reported a revenue from operations of ₹53.31 crore for FY 2025-26. The acquisition does not constitute a related party transaction, and no governmental or regulatory approvals are required for the deal to proceed.
Strategic Rationale and Financials
The acquisition aligns with Jagsonpal Pharmaceuticals' objective of strengthening its presence in the healthcare ecosystem by leveraging Aequitas's established relationships with leading hospital chains. Management stated that the hospital segment contributes approximately 10% of pharma industry sales and is growing faster than the retail prescription market. The transaction is intended to reduce the time required to build these relationships organically.
The deal involves the purchase of 85% of the paid-up equity share capital of Aequitas Healthcare. The current directors of the target company will retain the remaining 15% stake and continue to be associated with the business. The consideration of ₹20.8 crore will be funded from the internal accruals of Jagsonpal Pharmaceuticals.
Aequitas Healthcare Financial Performance
Aequitas Healthcare has recorded consistent revenue figures over the past three financial years. The company operates exclusively in India and focuses on the pharmaceutical and healthcare industry.
| FY | Turnover (in ₹ Crore) |
|---|---|
| 2025-26 | 53.31 |
| 2024-25 | 56.19 |
| 2023-24 | 53.71 |
Management Commentary
Manish Gupta, Managing Director of Jagsonpal Pharmaceuticals, described the acquisition as an important strategic milestone that provides a ready platform in the hospital segment. He emphasized that the company's portfolio of established brands would benefit from Aequitas's institutional relationships. Amrut Medhekar, Chief Operating Officer, noted that the transaction transforms the company into an omnichannel specialty healthcare business.
Shailesh Kamat, Director of Aequitas Healthcare, expressed confidence that the partnership would unlock new opportunities for stakeholders and benefit the healthcare ecosystem. J Sagar & Associates acted as legal advisors to Jagsonpal Pharmaceuticals, while Noverra Partners advised Aequitas Healthcare on the transaction.
Historical Stock Returns for Jagsonpal Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.16% | -2.77% | +12.48% | +28.59% | -0.14% | +233.71% |
How will Jagsonpal Pharmaceuticals integrate Aequitas Healthcare's distribution network to maximize cross-selling opportunities with its existing brand portfolio?
What specific revenue synergies does management expect to achieve by targeting the hospital segment, which currently accounts for 10% of industry sales?
Will the company pursue further acquisitions or strategic partnerships to expand its institutional footprint beyond Aequitas Healthcare's current network?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
